2020 achievements – Breakthrough Device Designation by FDA
In March 2020, the FDA granted Breakthrough Device Designation for the OncoSilTM System for the treatment of unresectable locally advanced pancreatic cancer (LAPC) in combination with systemic chemotherapy.
2020 achievements – participation in 4 major medical congresses
In 2020, OncoSil Medical had the opportunity to sponsor and virtually attend several major medical education events: the London Pancreas Workshop and the Pancreatic Cancer UK Annual Summit in September, the New-Zealand Society for Oncology Conference in October and the World Congress of the International Hepato-Pancreato-Biliary Association in November.
2020 achievements – the OncoSil Medical team has doubled in size
To support its growth plans, OncoSil Medical welcomed 10 new team members across Germany, Italy, the UK, Benelux and Australia. They joined the sales, marketing, regulatory affairs and quality, manufacturing and operations departments.